WST vs AVTR

For growth investors, West Pharmaceutical Services, Inc.

(WST) is the stronger pick with 6. 3% revenue growth year-over-year, versus -3. 4% for Avantor, Inc. (AVTR). West Pharmaceutical Services, Inc. (WST) offers the better valuation at 46. 0x trailing P/E (36. 3x forward), making it the more compelling value choice. Analysts rate West Pharmaceutical Services, Inc. (WST) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Avantor, Inc.

is actually cheaper at 10. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, West Pharmaceutical Services, Inc.

(WST) delivered a total return of -3. 9%, compared to -72. 8% for Avantor, Inc. (AVTR). Over 10 years, the gap is even starker: WST returned +353. 8% versus AVTR's -41. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), West Pharmaceutical Services, Inc.

(WST) is the lower-risk stock at 0. 92β versus Avantor, Inc. 's 1. 54β — meaning AVTR is approximately 68% more volatile than WST relative to the S&P 500. On balance sheet safety, West Pharmaceutical Services, Inc. (WST) carries a lower debt/equity ratio of 13% versus 71% for Avantor, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), West Pharmaceutical Services, Inc.

(WST) is pulling ahead at 6. 3% versus -3. 4% for Avantor, Inc. (AVTR). On earnings-per-share growth, the picture is similar: West Pharmaceutical Services, Inc. grew EPS 1. 6% year-over-year, compared to -175. 0% for Avantor, Inc.. Over a 3-year CAGR, WST leads at 2. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

West Pharmaceutical Services, Inc.

(WST) is the more profitable company, earning 16. 1% net margin versus -8. 1% for Avantor, Inc. — meaning it keeps 16. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WST leads at 20. 1% versus -3. 8% for AVTR. At the gross margin level — before operating expenses — WST leads at 35. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Avantor, Inc.

(AVTR) trades at 10. 7x forward P/E versus 36. 3x for West Pharmaceutical Services, Inc. — 25. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AVTR: 12. 7% to $9. 50.

In this comparison, WST (0.

3% yield) pays a dividend. AVTR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, West Pharmaceutical Services, Inc.

(WST) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92), +353. 8% 10Y return). Avantor, Inc. (AVTR) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WST: +353. 8%, AVTR: -41. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.